Shares of Femasys Inc. (FEMY) dropped 9.5% to $0.32 on June 5 after the women's health device maker disclosed a 1-for-20 reverse stock split — a last-resort move to avoid being kicked off the Nasdaq. The split takes effect at 4:30 p.m. Eastern today , and split-adjusted trading begins Monday, June 8 . For shareholders, it's a stark admission: the underlying business hasn't been able to push the stock above $1.00 on its own for nearly a year.

  • The Clock Was Already Ticking Toward Delisting. Nasdaq flagged Femasys in July 2025 for trading below the $1.00 minimum bid price for 30 consecutive business days. After two compliance windows, the company now has until July 13, 2026 to regain compliance. At today's pre-split price of $0.32, the post-split theoretical price lands around $6.40 — comfortably above the threshold, but only on paper. Reverse splits in micro-cap biotech stocks frequently trigger further selling as short-term traders exit, and historically many such stocks drift back below $1.00 within months.

  • Revenue Is Tiny and Cash Is Draining Fast. Q1 2026 sales came in at just $424,889, up 24.5% year-over-year , but that's barely material for a company burning millions quarterly. Cash stood at $5.4 million as of March 31, and management itself says that funds operations only into Q3 2026.

That's down from $9.3 million at year-end 2025 — a roughly $3.9 million quarterly cash drain. The company will almost certainly need to raise capital again, likely at dilutive terms given its micro-cap status.

  • The "Net Income" Headline Is Misleading. Femasys reported Q1 net income of $846,100, but that swung entirely on non-cash fair value adjustments to its warrant and conversion option liabilities — accounting gains that reflect the falling stock price, not operating improvement. The actual operating loss was still $4.2 million.

  • A Promising Pipeline Doesn't Pay the Bills Yet. With roughly 60.4 million shares outstanding pre-split , the post-split count drops to about 3 million shares — a thin float that could amplify volatility in either direction. Femasys has initiated its pivotal clinical trial for a non-surgical permanent birth control device , and its fertility product line is gaining early traction. But market-implied metrics indicate a "substantially elevated probability of financial distress." The split buys Nasdaq time; it doesn't buy runway. Investors should watch the next capital raise — that will determine whether the story survives.